Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01391611 |
Recruitment Status :
Terminated
(Lack of efficacy - Futility endpoint reached)
First Posted : July 12, 2011
Results First Posted : April 7, 2017
Last Update Posted : April 7, 2017
|
Sponsor:
Kristen Ganjoo
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Kristen Ganjoo, Stanford University
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Condition |
Gastrointestinal Stromal Tumor (GIST) |
Intervention |
Drug: Pazopanib |
Enrollment | 25 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | Pazopanib Arm |
---|---|
![]() |
Pazopanib: 800 mg; PO |
Period Title: Overall Study | |
Started | 25 |
Completed | 3 |
Not Completed | 22 |
Baseline Characteristics
Arm/Group Title | Pazopanib Arm | |
---|---|---|
![]() |
Pazopanib: 800 mg; PO | |
Overall Number of Baseline Participants | 25 | |
![]() |
[Not Specified]
|
|
Age, Continuous
Median (Full Range) Unit of measure: Years |
||
Number Analyzed | 25 participants | |
59
(27 to 72)
|
||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 25 participants | |
Female |
10 40.0%
|
|
Male |
15 60.0%
|
|
Ethnicity (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 25 participants | |
Hispanic or Latino |
1 4.0%
|
|
Not Hispanic or Latino |
22 88.0%
|
|
Unknown or Not Reported |
2 8.0%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 25 participants | |
American Indian or Alaska Native |
0 0.0%
|
|
Asian |
1 4.0%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
|
Black or African American |
3 12.0%
|
|
White |
18 72.0%
|
|
More than one race |
0 0.0%
|
|
Unknown or Not Reported |
3 12.0%
|
|
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
||
United States | Number Analyzed | 25 participants |
25 |
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Kristen Ganjoo, MD |
Organization: | Stanford University Medical Center |
Phone: | 650-725-6413 |
EMail: | kganjoo@stanford.edu |
Responsible Party: | Kristen Ganjoo, Stanford University |
ClinicalTrials.gov Identifier: | NCT01391611 |
Other Study ID Numbers: |
IRB-20636 RR2002/00017/09 ( Other Identifier: GlaxoSmithKline ) 11-311 ( Other Identifier: Stanford IRB alternate ) GIST0003 ( Other Identifier: OnCore ) |
First Submitted: | July 8, 2011 |
First Posted: | July 12, 2011 |
Results First Submitted: | December 19, 2016 |
Results First Posted: | April 7, 2017 |
Last Update Posted: | April 7, 2017 |